Enzyme Fragment Complementation Assay Technology
Enabling Technologies with a Flexible Platform
Eurofins DiscoverX®, an innovative biotechnology company, develops, manufactures, and commercializes reagents, complete assay kits, and turn-key solutions for the drug discovery, screening, and life science markets. Our products, biochemical and cell-based assays, enable customers to improve research productivity and effectiveness, thus accelerating the discovery and development of new drugs.
Eurofins DiscoverX's patented Enzyme Complementation Technology (EFC) technology offers drug discovery the means to interrogate biomolecular reactions for advancing therapeutic drug screening and development programs. EFC is a homogeneous detection assay system that enables you to measure and rank ligand potencies, discover the mechanism of action (MOA), perform binding and functional screens, identify novel compounds, and much more. As a robust and reliable assay technology EFC can be used for both cell-based (PathHunter®, KILR®, and InCELL platforms) and biochemical (HitHunter® platform) assay formats.
Directly Measure Relevant Target Biology with Ease
- Homogenous Format — Mix-and-read assay format that does not require washing, centrifugation, or filtration
- Robust — Enzymatically-amplified assays with a large signal-to-background ratios and high precision with Z' factors >0.7 and lot-to-lot reproducibility
- Qualified and Validated — Extensively optimized for hundreds of targets used for screening in billions of data points, and thousands of peer-reviewed publications
- Scalable — Easily scalable and HTS-friendly from 96- to 3456-well microplate format
EFC Technology Principle
EFC is based on two recombinant β-galactosidase (β-gal) enzyme fragments that act as an enzyme acceptor (EA) and an enzyme donor (ED). Separately, the fragments are inactive, but combined, they form an active enzyme that hydrolyzes its substrate to produce a chemiluminescence signal.